Lazard Ltd is a global financial advisory and asset management firm, founded in 1848 and organized as a Bermuda holding company with principal offices in New York, Paris, and London. Its Financial Advisory business provides independent advice to corporations, institutions, and governments on mergers and acquisitions, divestitures, restructurings, capital structure, and other strategic matters. Its Asset Management business offers investment management across asset classes for institutional and individual clients worldwide.
For the chemical industry, Lazard advises across commodity and specialty chemicals, polymers, and materials, supporting clients with portfolio reviews, carve-outs, cross‑border M&A, restructuring, and financing. Lazard Ltd is listed on the New York Stock Exchange.
Also known as Lazard Inc..
None yet. When a new project in the record names Lazard as owner, partner or investor, it shows here.
All-stock merger creates an integrated North American chemicals platform with vertical chlorine/caustic integration, ~$12.5B pro forma revenue and $400M+ identified synergies.
Divests evaporated salt business for €350–€380m to fund a new Resource Recovery segment focused on waste-to-energy and energy security.
Lilly acquires Orna to enhance genetic medicine and in vivo cell engineering, focusing on autoimmune diseases with circular RNA and lipid nanoparticle technology.
The divestments aim to optimize the portfolio, enhance cash flow, and focus on high-margin markets, while maintaining strategic access and customer service.
